



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
PATENT APPLICATION
OCT 08 2002
TECH CENTER 1600/2900
1614
10/11/02

Applicant(s): Chen et al.

Serial No.: 10/046,681

Group Art Unit No.: 1614

Filed: January 10, 2002

Examiner: n/a

For: SUBSTITUTED ALKYLAMINE DERIVATIVES AND
METHODS OF USE

BEST AVAILABLE COPY

Docket No.: A-733A

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Under the guidelines of 37 C.F.R. 1.97, applicants submits a copy of each of the references listed on the attached supplemental PTO-1449 (Modified) form for consideration by the Examiner.

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under section 1.114, whichever event occurs last. 37 CFR 1.97(b).

Applicants' requests consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc. An original and one copy of this paper are enclosed.

Respectfully submitted,

Joseph W. Bulock
Attorney/Agent for Applicant(s)
Registration No.: 37,103
Phone: (805) 447-7966
Date: September 27, 2002


Please send all future correspondence to:
U.S. Patent Operations/ JWBcpb
Dept. 4300, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

9/27/2002
Date

Carlton Berman
Signature



BEST AVAILABLE COPY

Sheet 1 Of 1

Modified Form PTO-1449

Atty. Docket No.

A-733A

Serial No.

10/046.681

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Chen et al.

Filing Date

January 10, 2002

Group

1614

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	A4.						
	A5.						
	A6.						
	A7.						
	A8.						
	A9.						

RECEIVED
OCT 08 2002
TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	B22.	WO 00/47212	8/17/2000	PCT			YES NO
	B23.						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C6.	Bold et al., "New Anilinothalazines as Potent and Orally Well Absorbed Inhibitors of the VEGF Receptor Tyrosine Kinases Useful as Antagonists of Tumor-Driven Angiogenesis." (2000) J. Med. Chem. 43:2310-2323.	
C7.	Hennequin et al., "Design and Structure-Activity Relationship of a New Class of Potent VEGF Receptor Tyrosine Kinase Inhibitor." (1999) J. Med. Chem. 42: 5369-5389.	
C8.	Sun et al., "Design, Synthesis, and Evaluations of substituted 3-[(3- or 4-Carboxyethylpyrrol-2-yl)methylidene]indolin-2-ones as Inhibitors of VEGF, FGF, PDGF Receptor Tyrosine Kinases." (1999) J. Med. Chem. 42: 5120-5130	
C9.		
EXAMINER:		Date Considered:
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		